XML 32 R10.htm IDEA: XBRL DOCUMENT v3.20.4
Cash Equivalents and Marketable Securities
 12 Months Ended
Dec. 31, 2020
Investments, Debt and Equity Securities [Abstract]  
Cash Equivalents and Marketable Securities CASH EQUIVALENTS AND MARKETABLE SECURITIES
The table below summarizes the Company’s cash equivalents and marketable securities (in thousands):
Amortized
Cost		Gross
Unrealized
Gains		Gross
Unrealized
Losses		Estimated
Fair Value
December 31, 2020
Cash equivalents:
Money market funds$53,165 $— $— $53,165 
Total53,165 — — 53,165 
Marketable securities:
Commercial paper213,500 41 (8)213,533 
Corporate debt securities59,575 16 (17)59,574 
Certificates of deposit12,311 — — 12,311 
Asset-backed securities17,905 10 (7)17,908 
U.S. government-sponsored entity debt securities257,284 19 (5)257,298 
Total560,575 86 (37)560,624 
Total cash equivalents and marketable securities$613,740 $86 $(37)$613,789 
December 31, 2019
Cash equivalents:
Money market funds$30,496 $— $— $30,496 
Commercial paper2,998 1 — 2,999 
Total33,494 1 — 33,495 
Marketable securities:
Commercial paper155,230 145 (7)155,368 
Corporate debt securities94,905 115 (3)95,017 
U.S. government-sponsored entity debt securities53,411 91 (9)53,493 
Total303,546 351 (19)303,878 
Total cash equivalents and marketable securities$337,040 $352 $(19)$337,373 

The fair value of marketable securities by contractual maturity were as follows (in thousands):
December 31,
20202019
Maturing in one year or less$510,094 $282,046 
Maturing after one year through five years50,530 21,832 
Total$560,624 $303,878 
The Company had no realized losses from the sale of marketable securities for the years ended December 31, 2020, 2019 or 2018. No investments were other-than-temporarily impaired at either December 31, 2020 or 2019. The Company considers factors such as the duration, the magnitude and the reason for the decline in value, the potential recovery period, creditworthiness of the issuers of the securities and its intent to sell. For marketable securities, it also considers whether (i) it is more likely than not that the Company will be required to sell the debt securities before recovery of their amortized cost basis, and (ii) the amortized cost basis cannot be recovered as a result of credit losses. No significant facts or circumstances have arisen to indicate that there has been any significant deterioration in the creditworthiness of the issuers of the securities held by the Company. Based on the Company’s review of these securities, including the assessment of the duration and severity of the unrealized losses and the Company’s ability and intent to hold the investments until maturity, there were no other-than-temporary impairments for these marketable securities at December 31, 2020.